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ttp://dx.doi.org/10.1016/j.ajpath.2014.10.015Myocardial infarction and coagulation disorders are leading causes of disability and death in the world.
An important role of the lectin complement pathway in myocardial infarction and coagulation has been
demonstrated in mice genetically deﬁcient in lectin complement pathway proteins. However, these
studies are limited to comparisons between wild-type and deﬁcient mice and lack the ability to examine
reversal/inhibition of injury after disease establishment. We developed a novel mouse that expresses
functional human mannose-binding lectin (MBL) 2 under the control of Mbl1 promoter. Serum MBL2
concentrations averaged approximately 3 mg/mL in MBL2þ/þMbl1/ Mbl2/ [MBL2 knock in (KI)]
mice. Serum MBL2 level in MBL2 KI mice signiﬁcantly increased after 7 (8 mg/mL) or 14 (9 mg/mL) days
of hyperglycemia compared to normoglycemic mice (P < 0.001). Monoclonal antibody 3F8 inhibited C3
deposition on mannan-coated plates in MBL2 KI, but not wild-type, mice. Myocardial ischemia/
reperfusion in MBL2 KI mice revealed that 3F8 preserved cardiac function and decreased infarct size and
ﬁbrin deposition in a time-dependent manner. Furthermore, 3F8 prevented ferric chlorideeinduced
occlusive arterial thrombogenesis in vivo. MBL2 KI mice represent a novel animal model that can be
used to study the lectin complement pathway in acute and chronic models of human disease.
Furthermore, these novel mice demonstrate the therapeutic window for MBL2 inhibition for effective
treatment of disease and its complications. (Am J Pathol 2015, 185: 347e355; http://dx.doi.org/
10.1016/j.ajpath.2014.10.015)Supported by NIH grants 5R01HL056086-17 and 5R01AI089781-03
(G.L.S.).
Disclosures: G.L.S. is listed as inventor on a patent on the use of
monoclonal antibody 3F8.The innate immune system plays an important role in host
defense. The complement system, as a part of the innate
immune system, is involved in protection against patho-
gens.1 The complement cascade can be activated/initiated
through three distinct pathways: classic, alternative, and
lectin. Lectin pathway (LP) activation is initiated by the
presence of speciﬁc structures on microorganisms (bacterial,
fungal, and some viral) binding to IgM or by changes in
glycosylation patterns on compromised cells.2e5 There are
several pattern recognition molecules that may be involved
in LP activation, such as mannose-binding lectin (MBL) 2
(Mbl1 and Mbl2 in mice), ﬁcolins (1, 2, and 3), and col-
lectin 11.6,7 These pattern recognition molecules are asso-
ciated with MBL-associated serine proteases (1, 2, and 3)
and can directly activate C4 and C2 in the LP.3,4,7e17 MBL
plays a signiﬁcant role as an initiation molecule thatstigative Pathology.
.recognizes endogenous ligands after oxidative stress and
tissue injury, ultimately leading to vascular wall remodeling,
thrombogenesis, and other cellular injuries.2,5,18e22
Studying the role of MBL in animal models of human
disease has been limited to comparison of wild-type (WT)
mice to Mbl-null mice, as well as reconstitution of Mbl-null
mice with human recombinant MBL2. There are no in-
hibitors to both murine Mbl1 and Mbl2, and this prevents
the study of the therapeutic window in animal models of
human disease. Furthermore, the lack of inhibitors to murine
Mbl1 and Mbl2 does not allow the study of disease suc-
cession or reversal of outcomes after MBL complex
Pavlov et alactivation in disease models. To circumvent these limita-
tions and to advance the ﬁeld, we generated a novel human
MBL2-expressing mouse that lacks murine Mbl1 and Mbl2.
We report that MBL2þ/þMbl1/ Mbl2/ (MBL2 KI) mice
produce functional human MBL2 and display LP activity
similar to WT mice. Furthermore, anti-MBL2 (clone 3F8)
monoclonal antibody (mAb) in the MBL2 KI mouse
signiﬁcantly protects the ischemic/reperfused murine
myocardium from loss of myocardial function, decreases
myocardial infarct size, and prevents myocardial ﬁbrin
deposition and occlusive thrombogenesis in vivo.
Materials and Methods
Animals
All procedures were reviewed and conducted according to
the institute’s Animal Care and Use Committee. All ex-
periments were performed under the standards and princi-
ples set forth in the Guide for the Care and Use of
Laboratory Animals.23
MBL2-Expressing Mice
Appropriate gene-targeted mouse CH57BL/6 embryonic stem
cells were generated to make a MBL2 cDNA knock-in mouse
in the Mbl1 locus using homologous recombination. Brieﬂy,
human MBL2 cDNA open reading frame sequence (approx-
imately 0.75 kb) was ampliﬁed from a human MBL2 cDNA
clone from GenBank (http://www.ncbi.nlm.nih.gov/nuccore/
NM_000242.2; Accession number NM_000242). The ﬁnal
targeting vector (Supplemental Figure S1) was obtained by
standard molecular cloning. Aside from the homology arms
and cDNA, the ﬁnal vector also contained ﬂippase recognition
target sequences ﬂanking the neomycin expression cassette
(ie, used for positive selection of the electroporated embryonic
stem cells) and a diphtheria toxin expression cassette (ie, used
for negative selection of the embryonic stem cells). The ﬁnal
vector was conﬁrmed by restriction digestion and sequencing
analysis. The restriction enzyme, NotI, was used for linear-
izing the ﬁnal vector before electroporation. Male chimeras
were bred with ﬂippase deleter mice, and germ-line trans-
mission was identiﬁed in four heterozygotes (two males and
two females). The MBL2þ/ mice were bred with CH57BL/6
Mbl-null mice (B6.129S4-Mbl1tm1Kata Mbl2tm1Kata/J; The
Jackson Laboratory, Bar Harbor, ME) and offspring screened
by PCR. After successful breeding strategies, the MBL2þ/þ
Mbl1/ Mbl2/ (MBL2 KI) mouse line was generated and
expanded.
CH57BL/6 (WT) mice (8 to 12 weeks old; Taconic Farms,
Hudson, NY) were used as background controls for MBL2
KI mice. Serum MBL2 concentrations in MBL2 KI mice
were measured in male and female mice, as previously
described.24 Serum MBL2 concentrations were also
measured after 7 or 14 days of hyperglycemia as described.25
C3 deposition on mannan-coated 384-well plates (M7504;348Sigma, St. Louis, MO) was analyzed as previously
described, but with modiﬁcations.24 Brieﬂy, 2% mouse sera
from WT or MBL2 KI mice were incubated on mannan-
coated plates in the presence of phosphate-buffered saline
(PBS; vehicle), 10 mg/mL anti-human MBL2 mAb (clone
3F8), or 100 mmol/L N-acetylglucosamine (GlcNAc;
Sigma). After incubation for 30 minutes at 37C, the plates
were washed (4) and mouse C3 deposition was detected
using goat anti-mouse C3 (MP Biomedicals, Santa Ana, CA)
and a donkey anti-goat IR Dye 800econjugated secondary
antibody (Rockland Immunochemicals, Gilbertsville, PA),
as previously described.24 Integrated intensity was measured
for each well (LiCor CLX, Lincoln, NE), and each experi-
ment was performed in triplicate six times.
Pharmacodynamic studies for the inhibition of sera MBL2
in the MBL2 KI mice were investigated. Brieﬂy, 50 mL of
mouse bloodwas collected by venipuncture andmAb 3F8was
given i.p. at 30, 100, 300, or 600 mg per mouse. Serial blood
samples (50 mL) were then taken daily for up to 7 days. MBL2
concentrations were measured as described.24
Murine MI/R Model
Themurinemyocardial ischemia and reperfusion (MI/R) model
was performed as described previously.22,26 After 45minutes of
ischemia, the myocardium was allowed to reperfuse for 5
minutes, 1 hour, or 4 hours. ECG changes (ie, ST segment)
were monitored and used to establish ischemia and reperfusion.
After reperfusion and echocardiography, the chest cavity was
opened and the heart was excised and ﬁxed overnight in 10%
neutral-buffered formalin or processed for infarct size.
The following groups ofMBL2KI mice were studied in the
MI/R protocols: i) sham MI/R (two WT and two MBL2 KI
mice) or MI/R treated with ii) PBS (control) or 3F8 (i.v.) as
follows: iii) at time of reperfusion (REP; 100 mg 3F8 per
mouse), iv) after 15 minutes of reperfusion (100 mg 3F8
per mouse), v) after 30minutes of reperfusion (100 mg 3F8 per
mouse), or vi) 1 hour before ischemia (100 mg 3F8 per mouse).
Infarct Size Measurements
Myocardial infarct size was performed with modiﬁcations, as
described.18,19,22,27 After 4 hours of reperfusion, the mice were
anesthetized with sodium pentobarbital. The chest cavity was
opened, and the heart was decompressed by cutting all venous
supply. The left anterior descending coronary artery ligation
was retightened. The heart was ﬂushed retrograde through the
thoracic aorta with 500 mL PBS and then perfused with 200
mL 5% Brilliant Blue G (Acros; Fisher Scientiﬁc, Pittsburgh,
PA). The hearts were excised and divided into cross sections
from base to apex into 1-mm slices with a coronal acrylic
matrix (Roboz; Surgical Instrument Co. Inc., Gaithersburg,
MD). Sections were incubated in 1% triphenyltetrazolium
chloride (Acros) at 37C for 15 minutes. Each section of the
heart was placed between two Gold Seal cover glasses (Erie
Scientiﬁc LLC, Portsmouth, NH). Images were taken with aajp.amjpathol.org - The American Journal of Pathology
Figure 1 A: Serum mannose-binding lectin 2 (MBL2) concentration in
male and female MBL2 KI mice. No signiﬁcant difference is found between
the groups. B: C3 deposition onto mannan-coated plates. Summary of C3
deposition for control (vehicle), 10 mg/mL 3F8, and 100 mmol/L
N-acetylglucosamine [GlcNAc; in wild-type (WT) and MBL2 KI sera].
Numbers within the bars represent number of experiments. C: Pharmaco-
dynamics of 3F8 in MBL2 KI mice. Baseline MBL2 levels were obtained at
day 0, followed by anti-MBL2 mAb 3F8 treatment (30, 100, 300, or 600 mg
per mouse, i.p.). 3F8 antibody dose dependently inhibits circulating MBL2
levels at a dose of 100 mg per mouse and higher. Data are means  SEM
(B). *P < 0.05 compared to respective control (vehicle; B).
Humanized MBL2 KI MouseNikon SMZ800 stereoscopic zoom microscope and digital
SPOT Insight camera (Diagnostic Instruments, Inc., Sterling
Heights, MI), and areas were calculated with ImageJ software
version 1.48 (NIH, Bethesda, MD). Infarct size was deter-
mined by calculating the total areas of the left ventricular free
wall, infarcted tissue, nonischemic tissue, and the ischemic
area at risk. The area at risk was not signiﬁcantly different
between groups (data not shown).
Echocardiography
Transthoracic echocardiography was used to evaluate car-
diac function, as described.19,20 Echocardiography was
performed 4 hours after reperfusion with a Philips Sonos
5500 instrument (Philips Medical Systems, Andover, MA)
with a 7- to 15-MHz probe. The mice were anesthetized
with sodium pentobarbital and placed on a heating table in a
supine position. Ejection fraction (EF) was evaluated by
long- and short-axis area measurements of the left ventricle
during systole and diastole, as described.19,20
Ferric Chloride Coagulation Model
The mouse ferric chloride coagulation model was used as
described.21,28,29 Isoﬂurane-anesthetized mice were placed in
a supine position, and the right common carotid artery was
exposed by blunt dissection. Carotid artery blood ﬂow was
measured with a Doppler ﬂow probe (Transonic Systems Inc.,
Ithaca, NY), as described.21 Whatman ﬁlter paper saturated
with 3.5% ferric chloride (FeCl3) was applied to either side of
the carotid artery, proximal to the Doppler ﬂow probe. The
ﬁlter papers were removed after 3 minutes, and blood ﬂowwas
measured continuously for 30 minutes. The mice were treated
with PBS (control; NZ 3) or 3F8 (300 mg; i.p.; 3 hours before
carotid artery ﬂow measurements; NZ 4).
Histological and Immunohistochemical Analysis
Myocardial sections (5 mm thick) were obtained and
deparafﬁnized using EZ-DeWax Solution (Biogenex, Fre-
mont, CA). After a brief rinse, the sections were subjected to
antigen retrieval by heating the slides in sodium citrate
buffer (10 mmol/L, pH 6.0) to 85C for 30 minutes.
Endogenous peroxidase was blocked with 3% H2O2 in
methanol/PBS (1:1 ratio) for 15 minutes, followed by
1-hour incubation with goat anti-mouse IgG Fab fragments
(MP Biomedicals, Solon, OH) (1:100 in PBS/0.05% Triton
X-100). The slides were rinsed in PBS, followed by a
30-minute incubation with normal goat serum (Vector
Laboratories, Burlingame, CA) (1:2 in PBS/0.05% Triton
X-100). Mouse b-ﬁbrin was localized with mAb 59D8 (a
gift from Dr. Charles Esmon (Oklahoma Medical Research
Foundation, Oklahoma City, OK)30; 1:500 in PBS/0.05%
Triton X-100) and goat anti-mouse IgG horseradish perox-
idase conjugated (Jackson ImmunoResearch, West Grove,
PA) (1:700 in PBS/0.05% Triton X-100 for 30 minutes).The American Journal of Pathology - ajp.amjpathol.orgThe sections were incubated with diaminobenzidine, and
ﬁbrin deposition was visualized with a Nikon Eclipse E400
microscope and analyzed using SPOT imaging software
version 5.1 (Diagnostic Instruments, Inc.).
Mouse b-ﬁbrin deposition analysis was performed by
ImageJ software. Because ﬁbrin deposition was localized in
the left ventricle, the percentage area of ﬁbrin deposition349
Pavlov et alwas acquired by measuring the total area positively stained
for ﬁbrin within the ischemic/reperfused left ventricle using
the region of interest tool in ImageJ software.
Statistical Analysis
All statistical analysis was performed with SigmaPlot 12.5
software (SPSS, Chicago, IL). Data are presented as
means SEM. Student’s t-test, one-way analysis of variance,
and the Student-Newman-Keuls test were used to demonstrate
signiﬁcance between groups. A one-way repeated-measures
analysis of variance and Student-Newman-Keuls test were
used to demonstrate signiﬁcance between the two groups over
time. P < 0.05 was considered statistically signiﬁcant.350Results
MBL2-Expressing Mouse Model
Functional serum MBL2 expression was evaluated in male
and female MBL2 KI mice using mannan-coated plates
(Figure 1A). MBL2 levels in males and females averaged
3.1  0.2 mg/mL. There was no signiﬁcant difference be-
tween male and female serum MBL2 levels. To evaluate the
ability of MBL2 to respond as an acute phase protein under
control of the Mbl1 promoter, we measured MBL2 after
hyperglycemia induction in male mice. MBL2 levels were
signiﬁcantly increased after 7 days [7.7  1.1 mg/mL (range,
4.2 to 11.7 mg/mL); N Z 7] or 14 days [8.6  0.7 mg/mL
(range, 5.9 to 11.0 mg/mL); N Z 8] of hyperglycemia
compared to normoglycemic [3.2  0.3 mg/mL; (range, 1.2
to 6.4 mg/mL); NZ 28] male mice (P < 0.001). There was
no signiﬁcant difference in serum MBL2 levels after 7 or 14
days of hyperglycemia.
Functional evaluation of LP activation (ie, MBL2 com-
plexed with mouse complement proteins) was evaluated
ex vivo in WT and MBL2 KI mice by observing C3 depo-
sition on mannan-coated plates. WT and MBL2 KI sera
deposited similar levels of mouse C3 on mannan-coated
plates, suggesting equivalent LP activation (Figure 1B).
C3 deposition was signiﬁcantly inhibited by 100 mmol/L
GlcNAc in WT or hMBL KI sera and demonstrates the
complete inhibition of mouse Mbl1 and Mbl2 in WT mice,
as well as the human MBL2 complex in the MBL2 KI mice.
In sharp contrast, anti-MBL2 mAb 3F8 did not inhibit
mouse C3 deposition in WT sera. However, C3 deposition
from MBL2 KI sera was signiﬁcantly inhibited by mAb 3F8
to the same level as GlcNAc. These data demonstrate that
the LP was activated in the serum of MBL2 KI mice to the
same extent as WT mice and demonstrate the ﬁrst biological
available to inhibit total MBL2 in a mouse model.Figure 2 A: Myocardial ejection fraction (EF) measurements. EF was
assessed in sham myocardial ischemia and reperfusion (MI/R) (sham) mice
and in mice after 45 minutes of ischemia and 4 hours of reperfusion. Sum-
mary of murine myocardial EF data for control [phosphate buffered saline
(PBS), i.v.] or 3F8 treated (100 mg per mouse, i.v.) at 0 (REP), 15 (15 minutes
REP), or 30 (30 minutes REP) minutes after reperfusion. The number of ex-
periments is identiﬁed within the bars. B: Representative images of
myocardial slices after MI/R (45 minutes or 4 hours) and tetrazolium chloride
staining in control (PBS, i.v.) or 3F8 treatment (100 mg per mouse, i.v.) at
0 (REP), 15 (15 minutes REP), or 30 (30 minutes REP) minutes after reper-
fusion. Brilliant Blue G dye (blue) denotes the nonischemic area, whereas red
and white dyes demonstrate the area at risk (ischemic tissue). White (un-
stained) tissue denotes infarcted tissue, and red denotes viable tissue. C:
Percentage of infarcted left ventricle. The percentage of the infarcted area
was calculated from the weight of the area at risk (AAR), area of infarct, and
area of noninfarct. The AAR was not signiﬁcantly different between groups
(data not shown). The number of experiments is identiﬁed within the bars.
Data are means  SEM (A and C). *P < 0.05 compared to control (15 or 30
minutes of reperfusion), **P < 0.01 compared to control (15 or 30 minutes
of reperfusion), and ***P< 0.001 compared to sham, REP (15 or 30 minutes
of reperfusion) (A); *P < 0.05 compared to 15- and 30-minute REP groups,
***P < 0.001 compared to all treated groups (C).
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Figure 3 A: Representative micrographs of ﬁbrin staining (black) at 5
minutes and 1 hour of reperfusion in MBL2 KI mice treated with phosphate-
buffered saline (control) or 3F8 (100 mg per mouse, i.v.) before myocardial
ischemia and reperfusion (MI/R). Arrows denote ischemic/reperfused area
and where ﬁbrin staining would be located. B: Representative micrographs
of ﬁbrin staining (brown) at 5 minutes and 1 hour of reperfusion in MBL2 KI
mice treated with PBS (control). C: The percentage of ﬁbrin deposition
within the ischemic/reperfused left ventricle after 5 minutes or 1 hour of
reperfusion. Data are means  SEM (C). N Z 3 to 5 per group (C).
*P < 0.05 compared to 1-hour control; ***P < 0.001 compared to
respective time control and also comparing 1-hour to 5-minute control.
Original magniﬁcations: 1 (A); 20 (B).
Figure 4 3F8 inhibits ferric chlorideeinduced thrombogenesis in vivo.
Wild-type mice were treated with phosphate-buffered saline (control) or
3F8 (300 mg per mouse, i.p.) 3 hours before the application of ferric
chloride to the carotid artery. Blood ﬂow was continuously monitored in
both groups for 30 minutes after ferric chloride application. Data are
means  SEM. ***P < 0.001 compared to control.
Humanized MBL2 KI MouseThe pharmacodynamics of 3F8-inhibited MBL2 in MBL2
KI mice were evaluated. Anti-MBL2 mAb 3F8 (30, 100,
300, or 600 mg per mouse, i.p.) was given after a baseline
sera sample was obtained. 3F8 antibody dose dependently
inhibited circulating MBL2 levels in a time-dependent
manner (Figure 1C). At a dose of 100 mg per mouse andThe American Journal of Pathology - ajp.amjpathol.orghigher, complete inhibition of functional MBL2 levels was
obtained at 24 hours. At a dose of 300 or 600 mg per mouse,
MBL2 was functionally inhibited for up to 3 days. Complete
inhibition of MBL2 levels for up to 1 week was observed at
600 mg per mouse. These data demonstrate that complete
inhibition of MBL2 over various time spans can be obtained
using a single dose of 3F8.
3F8 Preserves Myocardial Function
Myocardial function after MI/R was evaluated in MBL2 KI
mice treated with 3F8 mAb. Untreated MBL2 KI (control)
mice had a myocardial EF of approximately 40% after MI/R
(Figure 2A), which is signiﬁcantly decreased from sham
MI/R mice. In contrast, treating MBL2 KI mice immediately
at reperfusion (REP) with 100 mg 3F8 per mouse signiﬁ-
cantly prevented MI/R-induced loss of cardiac function, and
the EF of the REP group was not signiﬁcantly different from
the sham group. Furthermore, treating MBL2 KI mice with
100 mg 3F8 per mouse after 15 or 30 minutes of reperfusion
also signiﬁcantly protected against loss of cardiac function
compared to the control; however, the magnitude of cardiac
protection was signiﬁcantly lower than that observed when
treatment was given immediately at reperfusion (REP
group). The data demonstrate a 3F8-induced protection from
MBL2-induced loss of cardiac function after MI/R, and the
therapeutic window decreases as reperfusion time increases.
3F8 Reduces Infarct Size
To determine whether 3F8 protects the myocardium from
infarction and reperfusion injury, we measured infarct size.
We observed that i.v. treatment with 100 mg 3F8 per mouse,
at 0, 15, or 30 minutes after reperfusion, signiﬁcantly pro-
tects MBL2 KI mice from myocardial infarction compared
with the control (Figure 2, B and C). Myocardial sections
from base to apex from representative myocardial slices351
Table 1 Summary of the Interactions between the Complement
and Coagulation Systems
Substrate Factor Reference
Activates/Cleaves
MASP1 Factor XIII, fibrinogen,
and thrombin
36e38
MASP2 Thrombin (through prothrombin) 39
MBL, MASP1,
and MASP2
Fibrin 36,40
C5a TF and tPA (through PAI-1) 41e44
C3a and C5a TF (through TNF-a and IL-6) 45e49
C3b Fibrin 50,51
MAC (C5-9) TF 52
Xa C3 and C5 53
Plasmin C3 and C5 54
Thrombin C3, C5, and DAF 54,55
Platelets C3 56,57
Fibrin Complement 58
Inactivates
Heparin Classic and alternative
complement pathways
59,60
DAF, decay-accelerating factor; MASP, mannose-binding lectin (MBL)-
associated serine proteases; PAI, plasminogen activator inhibitor; TF, tissue
factor; TNF, tissue necrosis factor; tPA, tissue plasminogen activator.
Pavlov et alfrom the four groups of mice studied are presented in
Figure 2B. Similar to the EF data (Figure 2A), myocardial
infarction size was signiﬁcantly smaller if the treatment
started at reperfusion (0 minutes of reperfusion; REP) and
infarct size increased if treatment was delayed (Figure 2C).
Thus, anti-MBL2 antibody preserves myocardial function,
as well as myocardial tissue, from MI/R injury within a
short therapeutic window.
3F8 Prevents Fibrin Deposition within Myocardium
Hearts were evaluated for b-ﬁbrin deposition after MI/R,
because recent studies demonstrate a link between LP
activation and coagulation in vivo.21,22,31 b-Fibrin deposi-
tion was increased within the left ventricular free wall that
was subjected to ischemia/reperfusion in control mice after
5 minutes of reperfusion and decreased after 1 hour of
reperfusion (Figure 3A). Mouse b-ﬁbrin deposition was
mainly vascular and perivascular at 5 minutes of reperfu-
sion, and by 1 hour, b-ﬁbrin was mainly within the inter-
stitium (Figure 3B). Compared to control, 3F8-treated mice
had signiﬁcantly less left ventricular b-ﬁbrin deposition at
both time points (Figure 3, A and C). These data support the
hypothesis that inhibiting MBL2 reduces b-ﬁbrin formation
during reperfusion of the ischemic myocardium, in addition
to the cardioprotection observed in myocardial EF and
infarct size.
3F8 Prevents Occlusive Arterial Thrombogenesis
Our previous studies have demonstrated that Mbl-null mice
do not develop an occlusive thrombus in response to ferric
chloride compared to WT mice.21,22,31 MBL2 KI mice (PBS
treated; control) developed an occlusive thrombus within 15
minutes after ferric chloride application (Figure 4). In
contrast, treatment of MBL2 KI mice with 300 mg 3F8
completely inhibited ferric chlorideeinduced thrombo-
genesis. These results demonstrate that 3F8 signiﬁcantly
prevents occlusive arterial thrombogenesis in vivo in
response to ferric chloride in the MBL2 KI mouse. These
data further demonstrate that all functional MBL in the
MBL2 KI mouse are of human origin. Furthermore, the
murine serine proteases associated with the MBL2 complex
are sufﬁcient to induce thrombogenesis in vivo and are
completely inhibited by anti-MBL2 mAb.
Discussion
Studying the role of complement in human disease by using
animal models has been fraught with many challenges. First,
most complement inhibitors designed for use in humans do not
cross-react with the same complement components in other
species. Second, the use of complement-deﬁcient animals
relies on comparison with complement-sufﬁcient/WT litter-
mates or by reconstitution with recombinant or isolated pro-
teins to re-establish theWT phenotype in the deﬁcient animals.352Third, with regard to the study of the LP, unlike humans,
which have one functionalMBL2 protein, most animal species
have two functional MBL molecules (eg, Mbl1 and Mbl2).
Regarding these limitations, it then becomes either impossible
or cost prohibitive to establish chronic animal models of
human disease or to establish a disease and then evaluate the
effectiveness of complement inhibition on disease stability
and/or reversal of injury. To address these limitations, we
generated a humanized mouse that expresses MBL2 under the
control of the Mbl1 locus and then removed both murine Mbl
forms (Mbl1 andMbl2) by breeding with the Mbl-null mouse,
so that only MBL2 remained.
The MBL2 KI mice display a phenotype that is similar, if
not identical, to a WT mouse. C3 deposition on mannan-
coated plates was inhibited by speciﬁc inhibition of MBL2
with mAb 3F8 in MBL2 KI serum, whereas WT serum was
not inhibited. The magnitude of LP inhibition by 3F8 was
the same as GlcNAc and, thus, demonstrates that only
MBL2 is present in the MBL2 KI mouse. Pharmacodynamic
studies demonstrated that a single dose of mAb 3F8
inhibited MBL2 for at least 7 days. Because mAb 3F8 is a
mouse anti-human MBL2 inhibitory antibody, we believe
that repeat doses of 3F8 will unlikely establish an immune
response and that MBL2 could be inhibited for many weeks,
if not months, in the MBL2 KI mouse. Thus, the combined
use of MBL2 KI mice and mAb 3F8 makes an ideal pair of
reagents to study the long-term actions of MBL2 in chronic
murine models of human disease.
Baseline serum MBL2 expression in the MBL2 KI mouse
averages approximately 3 mg/mL, which is approximately
half the concentration observed for Mbl1 in the inbred
CH57BL/6J mouse.6 We designed the targeting vector forajp.amjpathol.org - The American Journal of Pathology
Humanized MBL2 KI MouseMBL2 insertion to the Mbl1 locus, because this promoter
region reportedly mimics that of the MBL2 locus and
displays acute phase activity, whereas the Mbl2 locus
maintains constitutively expressed Mbl2.6 Serum MBL2
expression signiﬁcantly increased over time in a hypergly-
cemia model (streptozocin injection), such that serum
MBL2 levels doubled over 7 to 14 days of hyperglycemia.
Thus, we demonstrate that the Mbl1 promoter region up-
regulates MBL2 expression in the MBL2 KI mice during
stress.
We have previously demonstrated that MBL is the initi-
ating molecule that activates complement and the LP after
MI/R.19 We demonstrate in the present study that MBL2
inhibition protects the ischemic/reperfused myocardium
from loss of EF and myocardial infarction, further demon-
strating that these mice lack functional murine Mbl1 and
Mbl2. The greatest protection of myocardial function (EF)
and structure was observed when 3F8 was given at the time
of reperfusion. However, the therapeutic window in MI/R is
much shorter in murine MI/R compared to the 18-hour
therapeutic window observed in murine stroke.32 Further-
more, clinical studies conducted in the Assessment of
Pexelizumab in Acute Myocardial Infarction trial showed no
beneﬁt from C5 inhibition by pexelizumab.33 We believe
that the failure of the Assessment of Pexelizumab in Acute
Myocardial Infarction trial was due to late administration of
the drug (median of 2.8 hours after onset of pain) and
continuous formation of the terminal complement complex.
Because low MBL2 levels are associated with decreased
injury in humans undergoing stroke or myocardial infarc-
tion, our data suggest that anti-MBL2 therapy should be
given early in the reperfusion phase of myocardial reper-
fusion to maximize outcomes.34,35
Speciﬁc interactions between the coagulation and com-
plement systems exist (Table 1). Until recently, these
complex interactions have been demonstrated in vitro using
reductionist models. The ferric chloride model of occlusive
thrombosis is a widely used model for drug design, target
validation, drug discovery, and evaluation of inhibitors for
platelet function, thrombin, and speciﬁc actions of almost all
proteins involved in coagulation and thrombolysis; thus, it is
an appropriate model for evaluation of anti-coagulation
preclinical studies.61 We demonstrated a central role of the
MBL complex in ferric chlorideeinduced thrombogenesis
in vivo.21,22,31 Herein, 3F8 signiﬁcantly inhibited ferric
chloridedinduced thrombus formation. 3F8 also inhibited
b-ﬁbrin deposition after MI/R. Interestingly, b-ﬁbrin depo-
sition within the reperfused myocardium moved over time
from a vascular/perivascular to interstitial location and
suggests signiﬁcant alterations to vascular permeability after
MI/R that is also inhibited by anti-MBL2 mAb. Additional
studies for this hypothesis are warranted. Thus, MBL2 in-
hibition, which also inhibits MBL-associated serine protease
1 and 2 function within the MBL complex, protects the
myocardium from tissue inﬂammation, intravascular coag-
ulation, and cellular injury after MI/R.18,19The American Journal of Pathology - ajp.amjpathol.orgIn conclusion, we developed a novel humanized MBL2-
expressing mouse under the control of the Mbl1 promoter,
which displays acute phase activity. By using this novel
mouse, we expanded the ﬁndings of a role for MBL in MI/R
by showing MBL-mediated b-ﬁbrin deposition and also a
short therapeutic window. This novel mouse will advance
the ﬁeld by being able to establish disease and then
observing if MBL2 inhibition reverses injury or halts its
progression. Furthermore, for the ﬁrst time, chronic murine
models of disease can be effectively evaluated for LP
contribution. Moreover, the MBL2 KI mouse will be
effective for drug design, target validation, and drug dis-
covery for the LP.Acknowledgment
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